The global cancer immunotherapy market size is likely to reach USD 127.2 billion by 2026, exhibiting a CAGR of 9.7% during the forecast period 2019 to 2026.
The growing incidences of cancer and a need to treat them is the key driver of the global immunotherapy market. The number of deaths occurring due to cancer is increasing every year and has therefore forced government bodies to take initiatives for the improvement of the health conditions of people, by investing heavily in research and development and enabling innovation and advancements in technology so as to offer improved treatments. This has pushed the growth of the global cancer immunotherapy therapy. As immunotherapy therapy has a higher success rate and proven efficiency over conventional treatment methods for cancer, its demand is higher and therefore, the market is expected to witness a remarkable growth over the coming years. The treatment pipeline looks promising and is thus, expected to ensure a healthy growth of the market.
The report offers forecasts of the overall cancer immunotherapy market over the global level as well as on regional levels. The estimated size of each of the segments and sub-segments has also been given in the report. Macroeconomic indicators, drivers, and restraints impacting the global cancer immunotherapy market have been included along with their impact on each region. Current challenges met by players in the cancer immunotherapy market have been elaborated on, thus giving a brief idea to readers and investors the problems they may encounter while investing in the competitive market.
Trends and Drivers
The global cancer immunotherapy market is expected to hold promising growth as there lies immense scope for improvement and development. The increasing number of clinical trials held particularly in immunotherapy is expected to boost the market’s growth. With the recognition from various medical bodies as the foremost line of therapy over conventional chemotherapy, cancer immunotherapy is estimated to hold immense potential and growth opportunity in the coming years.
However, factors such as high attrition rates during product development phase are anticipated to restrict the growth of the market. Also, an overall lack of awareness about immunotherapy being a better treatment option will impede the growth of the market. The high cost of clinical trials poses a challenge for players in the market. With many types and subtypes of cancer, having a single mode of treatment method is impossible, increasing the attrition rates of new drugs and treatments. Only a handful of contenders in the pipeline pass through the phase III trials and the rest are considered to be inefficient. This is yet another challenge faced by players in the market.
Segmentation
On the basis of therapeutic area, the market is segmented into colorectal cancer, lung cancer, breast cancer, melanoma, prostate cancer, and blood cancer. By end users, the global cancer immunotherapy market is segmented into ASC’s (ambulatory surgical centers), hospitals, clinics, and cancer research centers. Hospitals are expected to be the leading segment in the market. On the basis of region, the market is segmented into North America, Europe, Asia-Pacific, Latin America and the Middle East and Africa. Asia Pacific is poised to witness significant growth in the market.
Key Players Mentioned in this Report are:
The report provides studies key players operating in the market. Some of the key players in the global cancer immunotherapy market are: F.Hoffmann-La Roche Ltd., AstraZenca Plc, Eli Lilly and Company, Amgen, Inc., Bristol-Myers Squibb Company, GlaxoSmithKline Plc., Novartis AG, Pfizer, Inc., Janssen Biotech, Inc., Merck & Co., Inc., Janssen Biotech, Inc., Merck & Co., Inc., Sanofi, Takeda Pharmaceuticals, and Spectrum Pharmaceuticals, Inc.
The report segments the global cancer immunotherapy market as:
By Geography (Revenue, USD Billion, 2016 - 2026)
This report gives you access to decisive data such as:
Key highlights of this report
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. Market Dynamics Analysis and Trends
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
Chapter 6. Competitive Landscape
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
Chapter 7. Global Cancer Immunotherapy Market, By Product
7.1. Cancer Immunotherapy Market, By Product, 2021-2028
7.1.1. Monoclonal Antibodies
7.1.1.1. Market Revenue and Forecast (2016-2028)
7.1.2. Immunomodulators
7.1.2.1. Market Revenue and Forecast (2016-2028)
7.1.3. Oncolytic Viral Therapies and Cancer Vaccines
7.1.3.1. Market Revenue and Forecast (2016-2028)
Chapter 8. Global Cancer Immunotherapy Market, By Cancer Type
8.1. Cancer Immunotherapy Market, By Cancer Type, 2021-2028
8.1.1. Lung Cancer
8.1.1.1. Market Revenue and Forecast (2016-2028)
8.1.2. Breast Cancer
8.1.2.1. Market Revenue and Forecast (2016-2028)
8.1.3. Colorectal Cancer
8.1.3.1. Market Revenue and Forecast (2016-2028)
8.1.4. Melanoma
8.1.4.1. Market Revenue and Forecast (2016-2028)
8.1.5. Prostate Cancer
8.1.5.1. Market Revenue and Forecast (2016-2028)
8.1.6. Head and Neck Cancer
8.1.6.1. Market Revenue and Forecast (2016-2028)
8.1.7. Ovarian Cancer
8.1.7.1. Market Revenue and Forecast (2016-2028)
8.1.8. Pancreatic Cancer
8.1.8.1. Market Revenue and Forecast (2016-2028)
Chapter 9. Global Cancer Immunotherapy Market, Regional Estimates and Trend Forecast
9.1. North America
9.1.1. Market Revenue and Forecast, By Product (2016-2028)
9.1.2. Market Revenue and Forecast, By Cancer Type (2016-2028)
9.1.3. U.S.
9.1.3.1. Market Revenue and Forecast, By Product (2016-2028)
9.1.3.2. Market Revenue and Forecast, By Cancer Type (2016-2028)
9.1.4. Rest of North America
9.1.4.1. Market Revenue and Forecast, By Product (2016-2028)
9.1.4.2. Market Revenue and Forecast, By Cancer Type (2016-2028)
9.2. Europe
9.2.1. Market Revenue and Forecast, By Product (2016-2028)
9.2.2. Market Revenue and Forecast, By Cancer Type (2016-2028)
9.2.3. UK
9.2.3.1. Market Revenue and Forecast, By Product (2016-2028)
9.2.3.2. Market Revenue and Forecast, By Cancer Type (2016-2028)
9.2.4. Germany
9.2.4.1. Market Revenue and Forecast, By Product (2016-2028)
9.2.4.2. Market Revenue and Forecast, By Cancer Type (2016-2028)
9.2.5. France
9.2.5.1. Market Revenue and Forecast, By Product (2016-2028)
9.2.5.2. Market Revenue and Forecast, By Cancer Type (2016-2028)
9.2.6. Rest of Europe
9.2.6.1. Market Revenue and Forecast, By Product (2016-2028)
9.2.6.2. Market Revenue and Forecast, By Cancer Type (2016-2028)
9.3. APAC
9.3.1. Market Revenue and Forecast, By Product (2016-2028)
9.3.2. Market Revenue and Forecast, By Cancer Type (2016-2028)
9.3.3. India
9.3.3.1. Market Revenue and Forecast, By Product (2016-2028)
9.3.3.2. Market Revenue and Forecast, By Cancer Type (2016-2028)
9.3.4. China
9.3.4.1. Market Revenue and Forecast, By Product (2016-2028)
9.3.4.2. Market Revenue and Forecast, By Cancer Type (2016-2028)
9.3.5. Japan
9.3.5.1. Market Revenue and Forecast, By Product (2016-2028)
9.3.5.2. Market Revenue and Forecast, By Cancer Type (2016-2028)
9.3.6. Rest of APAC
9.3.6.1. Market Revenue and Forecast, By Product (2016-2028)
9.3.6.2. Market Revenue and Forecast, By Cancer Type (2016-2028)
9.4. MEA
9.4.1. Market Revenue and Forecast, By Product (2016-2028)
9.4.2. Market Revenue and Forecast, By Cancer Type (2016-2028)
9.4.3. GCC
9.4.3.1. Market Revenue and Forecast, By Product (2016-2028)
9.4.3.2. Market Revenue and Forecast, By Cancer Type (2016-2028)
9.4.4. North Africa
9.4.4.1. Market Revenue and Forecast, By Product (2016-2028)
9.4.4.2. Market Revenue and Forecast, By Cancer Type (2016-2028)
9.4.5. South Africa
9.4.5.1. Market Revenue and Forecast, By Product (2016-2028)
9.4.5.2. Market Revenue and Forecast, By Cancer Type (2016-2028)
9.4.6. Rest of MEA
9.4.6.1. Market Revenue and Forecast, By Product (2016-2028)
9.4.6.2. Market Revenue and Forecast, By Cancer Type (2016-2028)
9.5. Latin America
9.5.1. Market Revenue and Forecast, By Product (2016-2028)
9.5.2. Market Revenue and Forecast, By Cancer Type (2016-2028)
9.5.3. Brazil
9.5.3.1. Market Revenue and Forecast, By Product (2016-2028)
9.5.3.2. Market Revenue and Forecast, By Cancer Type (2016-2028)
9.5.4. Rest of LATAM
9.5.4.1. Market Revenue and Forecast, By Product (2016-2028)
9.5.4.2. Market Revenue and Forecast, By Cancer Type (2016-2028)
Chapter 10. Company Profiles
10.1. Amgen Inc.
10.1.1. Company Overview
10.1.2. Product Offerings
10.1.3. Financial Performance
10.1.4. Recent Initiatives
10.2. AstraZeneca
10.2.1. Company Overview
10.2.2. Product Offerings
10.2.3. Financial Performance
10.2.4. Recent Initiatives
10.3. F. Hoffman La Roche
10.3.1. Company Overview
10.3.2. Product Offerings
10.3.3. Financial Performance
10.3.4. Recent Initiatives
10.4. Bayer AG
10.4.1. Company Overview
10.4.2. Product Offerings
10.4.3. Financial Performance
10.4.4. Recent Initiatives
10.5. Bristol-Myers Squibb
10.5.1. Company Overview
10.5.2. Product Offerings
10.5.3. Financial Performance
10.5.4. Recent Initiatives
10.6. Eli Lilly and Co.
10.6.1. Company Overview
10.6.2. Product Offerings
10.6.3. Financial Performance
10.6.4. Recent Initiatives
10.7. Merck and Co.
10.7.1. Company Overview
10.7.2. Product Offerings
10.7.3. Financial Performance
10.7.4. Recent Initiatives
10.8. Novartis
10.8.1. Company Overview
10.8.2. Product Offerings
10.8.3. Financial Performance
10.8.4. Recent Initiatives
10.9. Pfizer
10.9.1. Company Overview
10.9.2. Product Offerings
10.9.3. Financial Performance
10.9.4. Recent Initiatives
Chapter 11. Research Methodology
11.1. Primary Research
11.2. Secondary Research
11.3. Assumptions
Chapter 12. Appendix
12.1. About Us
Glossary of Terms
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers